Finance

Photos likely show undeclared North Korea uranium enrichment site, analysts say By Reuters

;t=b.createElement(e);t.async=!0;t.src=v;s=b.getElementsByTagName(e);s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); https://i-invdn-com.investing.com/news/news_headline_open_108x81._800x533_L_1419519630.jpg https://www.investing.com/news/world-news/photos-likely-show-undeclared-north-korea-uranium-enrichment-site-analysts-say-3616525 Reuters

Shanghai braces for direct hit from Typhoon Bebinca By Reuters

leading-8"> SHANGHAI/BEIJING (Reuters) - Shanghai halted transportation links, recalled ships and shut tourism spots including Shanghai Disney Resort on Sunday as it...

Red Lobster’s 35-year-old CEO wakes up at 4 a.m.

Suns season tickets,” he said. “I used to go to games all the time for that, but then I moved. I live...

MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024 By Investing.com

;t=b.createElement(e);t.async=!0;t.src=v;s=b.getElementsByTagName(e);s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); https://i-invdn-com.investing.com/redesign/images/seo/investing_300X300.png https://www.investing.com/news/press-releases/macrogenics-announces-updated-efficacy--safety-data-from-tamarack-phase-2-study-of-vobra-duo-in-mcrpc-patients-at-esmo-congress-2024-93CH-3616520 Investing.com

23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study By Investing.com

;t=b.createElement(e);t.async=!0;t.src=v;s=b.getElementsByTagName(e);s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); https://i-invdn-com.investing.com/redesign/images/seo/investing_300X300.png https://www.investing.com/news/press-releases/23andme-therapeutics-announces-phase-2-results-for-two-additional-cancer-cohorts-and-correlative-biomarker-data-from-23me00610-study-93CH-3616521 Investing.com

Akeso Published First-Ever Efficacy Data for PD-1/VEGF Bispecific Antibody Ivonescimab with or without CD47 Antibody plus FOLFOXIRI for mCRC at ESMO 2024

;t=b.createElement(e);t.async=!0;t.src=v;s=b.getElementsByTagName(e);s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); https://i-invdn-com.investing.com/redesign/images/seo/investing_300X300.png https://www.investing.com/news/press-releases/akeso-published-firstever-efficacy-data-for-pd1vegf-bispecific-antibody-ivonescimab-with-or-without-cd47-antibody-plus-folfoxiri-for-mcrc-at-esmo-2024-93CH-3616522 Investing.com

Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024

;t=b.createElement(e);t.async=!0;t.src=v;s=b.getElementsByTagName(e);s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); https://i-invdn-com.investing.com/redesign/images/seo/investing_300X300.png https://www.investing.com/news/press-releases/akeso-published-ivonescimab-plus-ligufalimab-as-firstline-treatment-for-pdl1positive-recurrentmetastatic-head-and-neck-squamous-cell-carcinoma-at-esmo-2024-93CH-3616523 Investing.com

AI, Japan, Election: What changed this summer?

Investing.com

Latest articles

spot_imgspot_img